Next-Generation Sequencing-Based Clonality Assessment of Ig Gene Rearrangements: A Multicenter Validation Study by EuroClonality-NGS.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
09 2021
Historique:
received: 23 01 2021
revised: 17 05 2021
accepted: 01 06 2021
pubmed: 30 6 2021
medline: 5 2 2022
entrez: 29 6 2021
Statut: ppublish

Résumé

Ig gene (IG) clonality analysis has an important role in the distinction of benign and malignant B-cell lymphoid proliferations and is mostly performed with the conventional EuroClonality/BIOMED-2 multiplex PCR protocol and GeneScan fragment size analysis. Recently, the EuroClonality-NGS Working Group developed a method for next-generation sequencing (NGS)-based IG clonality analysis. Herein, we report the results of an international multicenter biological validation of this novel method compared with the gold standard EuroClonality/BIOMED-2 protocol, based on 209 specimens of reactive and neoplastic lymphoproliferations. NGS-based IG clonality analysis showed a high interlaboratory concordance (99%) and high concordance with conventional clonality analysis (98%) for the molecular conclusion. Detailed analysis of the individual IG heavy chain and kappa light chain targets showed that NGS-based clonality analysis was more often able to detect a clonal rearrangement or yield an interpretable result. NGS-based and conventional clonality analysis detected a clone in 96% and 95% of B-cell neoplasms, respectively, and all but one of the reactive cases were scored polyclonal. We conclude that NGS-based IG clonality analysis performs comparable to conventional clonality analysis. We provide critical parameters for interpretation and discuss a first step toward a quantitative scoring approach for NGS clonality results. Considering the advantages of NGS-based clonality analysis, including its high sensitivity and possibilities for accurate clonal comparison, this supports implementation in diagnostic practice.

Identifiants

pubmed: 34186174
pii: S1525-1578(21)00176-8
doi: 10.1016/j.jmoldx.2021.06.005
pii:
doi:

Substances chimiques

Immunoglobulin Heavy Chains 0
Immunoglobulin kappa-Chains 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1105-1115

Informations de copyright

Copyright © 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Michiel van den Brand (M)

Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: michiel.vandenbrand@radboudumc.nl.

Jos Rijntjes (J)

Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.

Markus Möbs (M)

Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany.

Julia Steinhilber (J)

Institute of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.

Michèle Y van der Klift (MY)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Kim C Heezen (KC)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Leonie I Kroeze (LI)

Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.

Tomas Reigl (T)

Molecular Medicine Program, Central European Institute of Technology, Brno, Czech Republic.

Jakub Porc (J)

Molecular Medicine Program, Central European Institute of Technology, Brno, Czech Republic.

Nikos Darzentas (N)

Molecular Medicine Program, Central European Institute of Technology, Brno, Czech Republic; Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany.

Jeroen A C W Luijks (JACW)

Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.

Blanca Scheijen (B)

Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.

Frédéric Davi (F)

Hematology Department, Hospital Pitié-Salpêtrière and Sorbonne University, Paris, France.

Hesham ElDaly (H)

Histopathology Department, Coventry University Hospitals National Health Service Trust, Coventry, United Kingdom; Clinical Pathology Department, Cairo University, Cairo, Egypt.

Hongxiang Liu (H)

Haematopathology and Oncology Diagnostics Service, Addenbrooke's Hospital, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom.

Ioannis Anagnostopoulos (I)

Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany.

Michael Hummel (M)

Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany.

Falko Fend (F)

Institute of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.

Anton W Langerak (AW)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Patricia J T A Groenen (PJTA)

Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH